Skip to main content
MyDeficiencies

Sertraline

SSRI

Also sold as Zoloft.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Sertraline undergoes extensive first-pass hepatic metabolism (principally N-demethylation; the label does not name a single dominant CYP isoform for this step), is a weak-to-moderate CYP2D6 inhibitor with no clinically meaningful CYP3A4 inhibition and only a marginal, non-clinically-significant induction signal (a 5% reduction in antipyrine half-life), and is cleared mainly as metabolites (about 40-45% urinary, 40-45% fecal including 12-14% unchanged parent drug). It is 98% protein-bound, orally absorbed with a small food-related increase in exposure, and has an average terminal half-life of about 26 hours. None of this constitutes a chelation, gastric-pH, or bile-acid mechanism, so the classical absorption-interference pathway that drives many drug-nutrient depletion stories is largely absent for sertraline. The real, drug-specific signal instead comes from two other directions. First, sertraline carries a labeled, mechanistically named risk of SIADH-mediated dilutional hyponatremia, and this dossier found two independent, sertraline-stratified meta-analyses (one general-population, one geriatric-specific) confirming a statistically significant, clinically meaningful elevation in hyponatremia risk versus non-use, even though sertraline sits toward the lower-risk end within the SSRI class itself; this is graded red. Second, across the seven required physiological categories, the best-supported and most consistent finding is direct mitochondrial electron transport chain inhibition, replicated across three independent research groups using three different tissue models (rat hepatocytes/isolated liver mitochondria, isolated pig brain mitochondria, and human stem-cell-derived cardiac organoids at a clinically relevant 30 nM concentration), with a genuinely mixed ATP-output picture disclosed rather than smoothed over. Sertraline also shows real, well-replicated in vitro antimicrobial potency against several gut-relevant bacterial species, among the strongest of the SSRIs tested, though no human study has isolated sertraline's own compositional effect from its SSRI/SNRI classmates. Oxidative stress and oxygen delivery/utilization both returned genuinely mixed, tissue- or context-dependent human and in vitro signals, graded orange and bounded accordingly rather than forced toward a single clean direction.

SSRI, serotonin transporter (SERT) inhibitor · ATC N06AB06 · also sold as Zoloft · reviewed 2026-09-29. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Sertraline in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Sodium, SIADH-mediated dilutional hyponatremia, comparatively lower-risk SSRI but still significantly elevated

Red — Severe

See study details

Sertraline carries a labeled, mechanistically named risk of SIADH-mediated hyponatremia, confirmed by two independent, sertraline-stratified meta-analyses with statistically significant, clinically meaningful risk elevation, particularly in elderly patients and in the first weeks of treatment, even though sertraline ranks toward the lower-risk end within the SSRI class.

Full detail, limits and 1 references

What the grade means here: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence. Red

Limits on what this shows

  • Key negative/null findings: Both meta-analyses independently and explicitly describe sertraline (with duloxetine) as among the lower-risk agents within their respective classes, and event rates, while statistically significant versus non-use, remain a minority of treated patients (2.52% in the general-population estimate; sertraline's SSRI-class comparator fluoxetine reached 6.51%). This bounding finding is reported here rather than omitted.
  • At-risk subgroups: Age 60 and older (reduced glomerular filtration rate, impaired urinary dilution capacity, increased renal ADH sensitivity), low body weight, concomitant diuretics or ACE inhibitors, and the first 2-4 weeks after starting or increasing the dose.
  • Counter-evidence on record: No source found contradicting the direction of the association; the consistent "lower risk within class" finding across both meta-analyses is itself disclosed as a bounding factor rather than a contradiction.

Regulatory status

Labeled directly: "Hyponatremia may occur as a result of treatment with SNRIs and SSRIs, including ZOLOFT... In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)." No specific incidence figure is given in the label itself.

Population evidence

Meta-analysis 1 (BMC Pharmacology and Toxicology, 2025; 38 observational studies, n=3,997,088, general adult population): sertraline specifically stratified from 9 studies, pooled event rate for any hyponatremia 2.52% (95% CI 0.81-7.55%); odds ratio from 4 studies = 2.346 (95% CI 2.178-2.527, p<0.001) versus non-use. Class-level SSRI event rate 5.98%, OR 2.158. Meta-analysis 2 (BMC Geriatrics, 2026; 21 cohort studies, n=2,115,187 adults aged 60+): sertraline-specific pooled event rate for any hyponatremia 9.32% (3 studies) and for clinically relevant hyponatremia 4.35% (2 studies); risk ratio versus non-users 4.03 (95% CI 2.55-6.39) for any hyponatremia and 4.73 (95% CI 2.48-9.02) for clinically relevant hyponatremia. Risk was highest in the first 2-4 weeks of treatment.

Mechanism

Named: serotonergic potentiation of arginine vasopressin (ADH) release and/or enhanced renal tubular sensitivity to ADH, producing SIADH and consequent water retention and dilutional hyponatremia; this is the mechanism the label itself cites.

Counter-evidence held on record

This is a retention/dilutional disturbance, not a sodium deficiency: it must never be presented as a reason to increase dietary sodium or salt intake, which would not address the underlying water-retention mechanism and could be actively unhelpful. Any suspected hyponatremia belongs with a prescriber for fluid-status evaluation and lab work, particularly in patients 60 or older or within the first weeks of treatment.

Vitamin D, low levels track with depression itself, not with sertraline exposure, confound disclosed

Yellow — Low

See study details

Depression and low vitamin D status are well documented to correlate, and this correlation predates and does not depend on antidepressant treatment; no sertraline-specific mechanism or study demonstrating that the drug itself lowers vitamin D was found, so this is graded as a context flag rather than a depletion finding.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: Because vitamin D status is typically already lower before treatment starts (a baseline, illness-associated pattern), a finding of "low vitamin D in sertraline-treated patients" would be expected even with zero drug effect; this is disclosed explicitly as confounding by indication, not resolved as either present or absent.
  • At-risk subgroups: Not established as sertraline-specific; the general depression-vitamin-D risk factors (limited sun exposure and reduced outdoor activity during depressive episodes) attach to the underlying condition, not uniquely to this drug.
  • Counter-evidence on record: No study was found showing sertraline treatment itself lowers vitamin D from a patient's own pre-treatment baseline in a controlled comparison.

Regulatory status

Not addressed in labeling. Sertraline has no gastrointestinal fat-malabsorption, bile-acid-sequestration, or clinically meaningful hepatic-enzyme-induction mechanism (only the 5% antipyrine-half-life signal, explicitly non-clinically-significant per the label) of the kind that plausibly accelerates vitamin D catabolism for drugs such as anticonvulsants or rifampin.

Population evidence

Multiple systematic reviews and meta-analyses (e.g., British Journal of Psychiatry and several 2022-2026 meta-analyses) consistently find lower vitamin D levels associated with depression and with depression severity, class-level, condition-linked findings not specific to any drug. A sertraline-specific interventional study (12-week prospective study of vitamin D supplementation added to sertraline in MDD patients) was identified but could not be fully retrieved during this review (its PDF exceeded this session's fetchable length); it tests supplementation as an add-on to sertraline rather than measuring sertraline's own effect on vitamin D status, so even its title does not establish a depletion mechanism, and it is listed in Sources but not used as supporting evidence, per the prohibition on citing unread sources.

Mechanism

Absent: the mechanism screen found no plausible absorption-interference, hepatic-induction, renal-wasting, or cofactor-antagonism pathway connecting sertraline specifically to vitamin D. The association in the literature runs through the underlying depressive illness (systemic inflammation, reduced sun exposure and outdoor activity, altered dietary pattern), not through the drug.

Counter-evidence held on record

Never present as "sertraline depletes vitamin D." The honest framing is that depression itself, independent of medication, is associated with lower vitamin D status; any vitamin D monitoring or supplementation decision should follow standard deficiency screening, not a belief that this specific drug is the cause.

Vitamin B12 and folate, baseline illness-linked association with depression and treatment response, not a demonstrated sertraline depletion effect

Yellow — Low

See study details

Low B12 and folate are associated with depression and, in some studies, with antidepressant response, but this reflects baseline nutritional status feeding into the illness and its treatment, not sertraline lowering either nutrient; no absorption-interference or other depletion mechanism connects sertraline specifically to B12 or folate.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: A large community-sample study found "no clear potentiation of antidepressant medication effects by folic acid + vitamin B12," a real null result for the augmentation-benefit hypothesis, disclosed here as relevant context even though it does not directly test a depletion mechanism.
  • At-risk subgroups: Not sertraline-specific; populations with pre-existing dietary B12/folate insufficiency (e.g., older adults, those with reduced dietary B12 or folate intake) carry their own baseline risk independent of sertraline.
  • Counter-evidence on record: No study found showing sertraline directly lowers B12 or folate from a patient's pre-treatment baseline.

Regulatory status

Not addressed in labeling.

Population evidence

A fluoxetine-specific (not sertraline) study of serum folate, B12, and homocysteine found low baseline folate predicted slower or poorer clinical improvement, a class-member, baseline-status finding rather than a sertraline depletion finding. A broader literature (including Coppen & Bolander-Gouaille's 2005 review and subsequent meta-analyses of folate/B12 augmentation trials) supports folate and B12 status as factors in depression and treatment response, again as baseline nutritional inputs, not as something SSRIs are shown to deplete. No sertraline-specific pre/post-treatment B12 or folate measurement study was found.

Mechanism

Absent: sertraline does not suppress gastric acid, does not bind intrinsic factor, and does not affect terminal-ileal absorption the way long-term acid suppression or metformin can; no renal-wasting or direct cofactor-antagonism mechanism is documented.

Counter-evidence held on record

Do not present as "sertraline causes B12 or folate deficiency." The literature supports the reverse-direction reading: baseline low B12/folate is associated with depression and, in some studies, with poorer antidepressant response, a reason to screen at baseline when clinically indicated, not a reason to attribute a low level to the drug.

Melatonin, class extrapolation from a fellow SSRI, not confirmed for sertraline itself

Yellow — Low

See study details

A study of fluoxetine, a fellow SSRI, reportedly found six weeks of treatment significantly reduced melatonin levels in both seasonal-affective-disorder patients and healthy volunteers; no sertraline-specific melatonin study was found, so this is graded as class extrapolation with a plausible shared mechanism.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: None found for sertraline specifically, since no sertraline-specific melatonin study was located. Both insomnia and sedation are commonly reported with sertraline, an inconsistent sleep-effect profile that does not cleanly support a single-direction melatonin claim on its own.
  • At-risk subgroups: Not established for sertraline.
  • Counter-evidence on record: Not established for sertraline specifically; the underlying fluoxetine source was not independently opened during this review, a limitation disclosed here rather than papered over.

Regulatory status

Not addressed in labeling.

Population evidence

Cited via a secondary consumer source referencing a primary fluoxetine melatonin study; that primary source was not independently opened during this review and is disclosed as such rather than treated as directly verified.

Mechanism

Plausible class mechanism: serotonin is the direct biosynthetic precursor of melatonin (via pineal AANAT/ASMT enzymes); chronic SERT blockade alters synaptic and potentially pineal serotonin availability, a mechanistically coherent though sertraline-unconfirmed pathway.

Counter-evidence held on record

Do not present as confirmed for sertraline; this is class extrapolation from one fellow SSRI (fluoxetine) with a plausible but unconfirmed shared mechanism. Melatonin supplementation carries its own interaction considerations with sertraline that belong with a prescriber, not a self-managed decision based on this entry.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden, electron transport chain inhibition replicated across three independent tissue models, no human confirmation

Yellow — Low

See study details

Three independent research groups, using three different tissue models spanning clinically relevant to supraphysiologic concentrations, found sertraline directly inhibits mitochondrial electron transport chain complexes and impairs mitochondrial respiration, a consistent, well-replicated Tier B signal with no human confirmation yet.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: No human in vivo mitochondrial-function study in sertraline-treated patients was found. The two isolated-mitochondria studies used concentrations (50-300 μmol/L) far above typical steady-state plasma sertraline levels (roughly 0.05-0.3 μmol/L), so their direct clinical translatability is uncertain; the third study's 30 nM concentration is disclosed here as the most clinically relevant of the three.
  • At-risk subgroups: Not established in humans; the cardiac-organoid study modeled fetal/developmental cardiac exposure, not general adult use.
  • Counter-evidence on record: None found showing sertraline protects or has no effect on mitochondrial respiratory function; the main limitation is concentration and tissue-model translatability to typical adult oral dosing, not a contradicting direction.

Regulatory status

Not addressed in labeling.

Population evidence

(1) Li & Couch, Toxicological Sciences, 2012 (rat primary hepatocytes and isolated rat liver mitochondria, sertraline 0-100 μM, 0.5-24h): inhibited Complex I and Complex V activity; uncoupled oxidative phosphorylation; rapidly and significantly depleted cellular ATP (p<0.001 vs control); induced Ca2+-dependent mitochondrial permeability transition (MPT); increased LDH leakage (cell death marker); effects attenuated by the MPT inhibitor bongkrekic acid. (2) Antioxidants (MDPI), 2023 (isolated pig brain mitochondria, sertraline 2.5-300 μmol/L alongside five other antidepressants): sertraline was the most potent Complex I inhibitor among the SSRIs tested (Complex I activity reduced 17.5±9.3% at 100 μmol/L; Complex II+III reduced 50.7±1.2%; Complex IV reduced 38.4±1.7%, all at 100 μmol/L); Complex I-linked respiration inhibited 24.5±10.4% at 50 μmol/L (IC50 12.4 μmol/L). (3) Sun et al., Communications Biology, 2025 (human pluripotent-stem-cell-derived cardiomyocytes, 2D monolayer and 3D organoids, sertraline 30 nM, a clinically relevant plasma-level concentration, 5 days): significantly reduced mitochondrial branch length and branch number (network fragmentation) alongside reduced ATP-linked, basal, and maximal respiration; proposed mechanism centers on PGAM5-driven excessive mitochondrial fission.

Mechanism

Named and convergent across all three: direct inhibition of respiratory chain complexes (most consistently Complex I), mitochondrial network fragmentation, and permeability-transition/fission-driven dysfunction.

Counter-evidence held on record

This is a mechanistic, non-human-confirmed signal: never present it as evidence of a systemic energy or mitochondrial-health deficiency in the general adult sertraline-using population, and never use it as grounds for mitochondrial-support supplementation. Shares underlying sources with ATP production and, for the cardiac-organoid study, with Oxidative stress; see Overlap map.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress, protective in a small human pilot, pro-oxidant in developing cardiac tissue in vitro, tissue-dependent and unresolved

Orange — Moderate

See study details

A small, non-randomized human pilot trial found sertraline significantly reduced a circulating lipid-peroxidation marker in depressed patients with chronic heart failure, while a separate in vitro human cardiac-tissue study at a clinically relevant concentration found increased reactive oxygen species; direction depends on the tissue and context measured, and this dossier discloses both rather than picking one.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. Orange

Limits on what this shows

  • Key negative/null findings: Arm B (untreated, depressed) showed no significant MDA change over the same 3 months, the key comparator null used here.
  • At-risk subgroups: Not established beyond the studied population (depressed patients with chronic heart failure); generalization to other populations is untested.
  • Counter-evidence on record: Sun et al., Communications Biology, 2025 (in vitro, human pluripotent-stem-cell-derived cardiomyocytes and 3D cardiac organoids, sertraline 30 nM, a clinically relevant plasma-level concentration, 5 days): reduced ATP production and mitochondrial respiration were accompanied by increased reactive oxygen species (see Mitochondrial burden and ATP production entries) - the opposite direction, measured at the cellular level in developing cardiac tissue rather than systemically in treated patients. No placebo-controlled human trial was found to adjudicate between these two real, drug-specific findings.

Regulatory status

Not addressed in labeling.

Population evidence

Sherwood et al., Journal of Cardiac Failure, 2011. Pilot study, 52 depressed chronic heart failure patients drawn from 254 screened hospitalized patients (28 sertraline-treated, "arm A"; 24 who declined antidepressant treatment, "arm B"), plus 40 nondepressed controls; 3-month follow-up, non-randomized. At baseline, depressed patients had significantly higher malondialdehyde (MDA) than nondepressed controls (3.2 vs 2.8 μmol/L, P=.02). At 3 months, arm A (sertraline) showed a significant MDA reduction (F=4.657, P=.037); arm B (untreated) showed no change. Depression scores (BDI 28±11 to 21±13, P=.008) and 6-minute walk distance (291±110 to 361±87 meters, P=.02) also improved with sertraline.

Mechanism

Not fully elaborated in the pilot; plausibly an indirect effect of reduced depression-associated systemic inflammation/oxidative burden as mood and function improve, rather than a direct pharmacologic antioxidant action of sertraline itself. Contrast the direct cellular mechanism in the counter-evidence below.

Counter-evidence held on record

Do not present as a settled "sertraline reduces oxidative stress" or "sertraline increases oxidative stress" claim; the direction found depends on whether the measurement is systemic/circulating in treated depressed patients (protective in this pilot) or cellular, in developing cardiac tissue in vitro (pro-oxidant). Never use either direction as grounds for antioxidant supplementation.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No tier B or C evidence, and no circulating consumer claim, connecting sertraline to copper status was found.

Full detail, limits and 2 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: The dual condition for ungraded is met on every channel that could be accessed across two separate research passes. Original pass: web searches across several phrasings (serum copper, ceruloplasmin, copper deficiency, trace elements) returned only a chemistry paper on a synthesized sertraline-copper coordination complex (drug-delivery chemistry, not patient copper status) and a case-control study (114 MDD patients, 50 controls) that measured serum copper across disease phases but found no significant difference between depressed patients and controls (0.81±0.27 vs 0.91±0.39 μg/mL, p>0.05) and did not analyze treatment-induced change by individual drug. Repair pass: PubMed's search-listing page for "sertraline copper" returned 7 results and was readable this time (no bot-verification challenge on that attempt); of these, two candidate titles were evaluated and both remain unopenable rather than supporting: Twayej et al. 2020 (World Journal of Biological Psychiatry, PMID 31062629, DOI 10.1080/15622975.2019.1612090, "Lowered zinc and copper levels in drug-naive patients with major depression: Effects of antidepressants, ketoprofen and immune activation"), re-attempted via the PubMed abstract page, the Crossref works API (returned bibliographic metadata only, no abstract field), Semantic Scholar, and the publisher page directly, all of which either returned no abstract text or a 403/429 response; and Uzbekov et al. 2006 (Human Psychopharmacology, PMID 16342231, "Biochemical profile in patients with anxious depression under the treatment with serotonergic antidepressants"), whose abstract likewise could not be retrieved through the PubMed detail page, NCBI eutils (blocked by that host's robots.txt), or Europe PMC. Neither source was cited as evidence per the prohibition on citing unread sources; both are newly logged in Sources as inaccessible. None of the consumer drug-nutrient-depletion sources reviewed for the circulating-claim audit named copper among the nutrients claimed to be depleted by SSRIs or sertraline. Sertraline's pharmacokinetic profile (Step 1) gives no plausible mechanism either: no chelation, no gastric-pH effect, no clinically meaningful hepatic enzyme induction, and no documented copper-cofactor dependency in its clearance pathway. Access note: during this repair pass, the Crossref, Europe PMC, Semantic Scholar, and OpenAlex APIs (both the search and the per-DOI lookup endpoints) again returned repeated 429/blocked responses; the proxy's own diagnostic endpoint confirmed these as gateway-level connection rejections (HTTP 403 on CONNECT to api.openalex.org, api.semanticscholar.org, www.ebi.ac.uk, api.crossref.org, and intermittently pubmed.ncbi.nlm.nih.gov) recurring in the same session window as the original review, not a fresh problem specific to this pass. This session's WebSearch allowance was already fully exhausted (0 of 200 remaining) at the start of this dedicated repair attempt, confirming that allowance is a session-wide budget a solo repair pass does not reset. This is disclosed as a tooling limitation, not treated as further confirming the gap.

Iron

Not graded — disclosed evidence gap

See study details

No tier B or C evidence, and no circulating consumer claim, connecting sertraline to iron status (ferritin, transferrin saturation, serum iron) was found; the adjacent RBC-count/hematocrit finding under Oxygen delivery/utilization does not measure iron status itself and was deliberately not used to support a grade here.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: The dual condition for ungraded is met on every channel that could be accessed across two separate research passes. Original pass: web searches (serum iron, ferritin, transferrin, iron chelation, restless legs syndrome mechanism) returned only generic drug-interaction-checker pages for concurrent iron supplement use (no mechanism or study), general iron/restless-legs-syndrome physiology unconnected to sertraline, and a genetic serotonin-deficient mouse erythropoiesis study (Wang et al., PNAS 2011) that tests serotonin absence, not SSRI treatment, correctly excluded per Hard Rule 6 as testing the reverse condition rather than SSRI-driven serotonin reuptake blockade. Repair pass: PubMed's search-listing pages were readable and were tried across four additional phrasings. "sertraline iron ferritin" returned zero results. "sertraline iron" returned 10 results, none a drug-nutrient status study (environmental photodegradation and wastewater-treatment chemistry, unrelated genetic/dermatology case reports, and one IL-6/hemodialysis sertraline trial with no iron-marker data in its title). "SSRI iron deficiency" returned 10 results dominated by the reverse-direction literature on iron deficiency's effect on the monoamine/serotonin transporter system in rats, itself excluded on the same reverse-causation logic as the mouse erythropoiesis study (iron status affecting serotonin signaling, not sertraline affecting iron status). "sertraline restless legs syndrome iron" returned zero results. One further title, "The Changes of Blood and CSF Ion Levels in Depressed Patients: a Systematic Review and Meta-analysis" (Meng et al., Molecular Neurobiology, 2024), surfaced once in a broader listing and could plausibly cover iron among other ions, but its PMID/DOI could not be confirmed and its abstract could not be retrieved before PubMed, Crossref, and Europe PMC all became unavailable for the remainder of this session; it is noted here as an unverified lead for a future revision, not cited as evidence, per the prohibition on citing unread sources. None of the consumer drug-nutrient-depletion sources reviewed named iron among the nutrients claimed to be depleted by SSRIs or sertraline. The RBC-count and hematocrit increase reported under Oxygen delivery/utilization concerns red-cell production, not ferritin, transferrin saturation, or other direct iron-status markers; using it here would double count one signal as two findings, so it remains intentionally excluded. Access note: during this repair pass, the Crossref, Europe PMC, Semantic Scholar, and OpenAlex APIs (both the search and the per-DOI lookup endpoints) again returned repeated 429/blocked responses, confirmed via the proxy's own diagnostic endpoint as gateway-level connection rejections (HTTP 403 on CONNECT) recurring in the same session window as the original review. This session's WebSearch allowance was already fully exhausted (0 of 200 remaining) at the start of this dedicated repair attempt. This is a disclosed tooling limitation, not a confirmed absence beyond what the channels actually used could show.
  • Meng Y, et al. The Changes of Blood and CSF Ion Levels in Depressed Patients: a Systematic Review and Meta-analysis. — Molecular Neurobiology, 2024. Surfaced once in a repair-pass PubMed listing while searching for sertraline/SSRI iron literature; scope (which ions, and whether drug-treated versus untreated patients are stratified) could not be confirmed.Could not be pinned down or opened: subsequent PubMed, Crossref, and Europe PMC attempts to retrieve its PMID/DOI and abstract were all blocked before completion. Logged as an unverified lead for a future revision, not cited as evidence for Iron or Copper.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk, among the most potent in vitro SSRI antimicrobials, not yet isolated from the SSRI/SNRI class in human data

Yellow — Low

See study details

Sertraline shows real, well-replicated in vitro antimicrobial potency against several gut-relevant bacterial species, among the strongest of the SSRIs tested, while the only human compositional data available groups sertraline with the SSRI/SNRI class rather than isolating it, and a related human infection-risk cohort found no sertraline-specific signal.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: The C. difficile cohort study's failure to find a significant sertraline-specific association, while finding one for mirtazapine and fluoxetine, is a real, informative null reported here rather than omitted; note this is a different endpoint (clinical infection risk) from the compositional in vitro/human findings above.
  • At-risk subgroups: Not established for sertraline specifically; the human compositional study population was MDD patients generally.
  • Counter-evidence on record: The BMC Medicine study's authors explicitly flag uncertainty over whether antidepressant-associated infection risk reflects "the pathophysiology of depression itself or the treatment for depression," i.e., confounding by indication is disclosed in that source and repeated here rather than resolved in the drug's favor.

Regulatory status

Not addressed in labeling.

Population evidence

McGovern, Hamlin & Winter, Australian & New Zealand Journal of Psychiatry, 2019 (narrative review compiling primary in vitro MIC data specific to sertraline): Staphylococcus aureus (MIC 4-160 mg/L across studies), Clostridium difficile (32-128 mg/L), Escherichia coli (4-128 mg/L), with markedly lower potency against Salmonella (>512 mg/L) and Serratia (256->512 mg/L); the review estimates colonic sertraline concentrations during once-daily dosing could exceed the MIC for a number of these species, and ranks sertraline and fluoxetine as the most antimicrobially potent SSRIs, attributed to higher lipophilicity (logP ~5.1). Separately, a cross-sectional two-cohort human study with meta-analysis (Communications Medicine, n=1,802 across the MACS and MIND-Set cohorts) found SSRI/SNRI-treated MDD patients had significantly lower Clostridium sensu stricto 1 abundance than unmedicated MDD patients (pFDR<0.05 in meta-analysis across both cohorts), but the authors state directly that "subgroups of individual antidepressants were generally small and highly imbalanced, precluding assessment of compound-level effects" - sertraline was included in the SSRI group but not isolated. A separate large population-based study (BMC Medicine, 2013; 16,781 community-based older adults plus a 4,047-patient hospital case-control cohort) analyzing individual antidepressants and hospital-acquired C. difficile infection risk found significant associations for mirtazapine (OR 2.14) and fluoxetine (OR 1.92), but did not analyze sertraline individually with its own risk estimate.

Mechanism

Named for the in vitro data: bacterial efflux-pump inhibition, interference with sodium-dependent bacterial amino-acid transporters, and reactive-oxygen-species generation, distinct from the DNA-gyrase mechanism proposed for tricyclic antidepressants. Plausible, though unconfirmed drug-by-drug, for the human compositional shift given shared SSRI pharmacology.

Counter-evidence held on record

The in vitro antimicrobial potency is real and drug-specific, but no human study has isolated sertraline's own compositional or clinical infection-risk effect from its SSRI/SNRI classmates. Do not present this as an established individual sertraline risk, and never suggest probiotic supplementation as a substitute for clinical monitoring or as an established remedy.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization, RBC count and hematocrit rose with treatment response in a small, drug-pooled adolescent cohort

Orange — Moderate

See study details

A small, drug-naive cohort found red blood cell count and hematocrit significantly increased after 12 weeks of SSRI treatment (sertraline or fluoxetine, pooled) specifically in patients who responded to treatment, a real but small, drug-pooled, response-correlated finding running opposite to a depletion narrative.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. Orange

Limits on what this shows

  • Key negative/null findings: Hemoglobin itself did not reach statistical significance in this cohort (trend only), and nonresponders showed no significant CBC change, arguing against a direct, response-independent pharmacologic effect.
  • At-risk subgroups: Not established; cohort was limited to drug-naive adolescents/young adults, so generalization to older or previously treated populations is untested.
  • Counter-evidence on record: Sertraline and fluoxetine were pooled rather than analyzed separately, so this cannot be isolated as a sertraline-specific effect, and the correlation with treatment "response" rather than with drug exposure alone raises confounding-by-clinical-improvement as an alternative explanation, disclosed here rather than treated as a clean causal drug effect.

Regulatory status

Not addressed in labeling for red-cell parameters. The label separately documents that sertraline blocks serotonin uptake into human platelets at clinically relevant doses, a platelet-function/bleeding-risk mechanism kept out of this entry per the distinction between a drug's intended pharmacology and a nutrient-style finding; see Monitoring panel.

Population evidence

Prospective cohort, Walailak University Hospital, Thailand, November 2020-March 2021; 45 drug-naive adolescents/young adults (median age 20.8 years, 66.7% female) with major depressive disorder, treated with fluoxetine or sertraline for 12 weeks; 25 (55.6%) treatment responders, 20 (44.4%) nonresponders. In responders: RBC count and hematocrit significantly increased, red cell distribution width (RDW) also increased, and hemoglobin showed a non-significant upward trend. No significant CBC change was reported in nonresponders. Higher baseline platelet count was associated with nonresponse.

Mechanism

Not established for sertraline directly; most plausibly a correlate of general health improvement with resolving depression (appetite, activity, sleep) rather than a direct pharmacologic effect on erythropoiesis. A genetic serotonin-deficient mouse model (Tph1 knockout, not an SSRI-treated model) has separately shown reduced red-cell survival and ineffective erythropoiesis, establishing that serotonin signaling is mechanistically relevant to erythropoiesis in principle, but that model tests serotonin absence, not SSRI-driven serotonin reuptake blockade, so it is disclosed as background plausibility only, not as direct support.

Counter-evidence held on record

This is a real human finding but not a green light or a warning: it should never be read as evidence that sertraline improves oxygen-carrying capacity in general use, nor as grounds for anemia concern. Standard CBC monitoring, when clinically indicated for other reasons, is reasonable; it is not a directive tied specifically to this finding.

ATP production, reduced in liver and cardiac tissue models, paradoxically increased in isolated brain mitochondria, unresolved discrepancy

Yellow — Low

See study details

The same three tissue models that show electron transport chain inhibition report a genuinely mixed ATP signal: ATP is rapidly depleted in rat hepatocytes and reduced in human cardiac organoids at a clinically relevant concentration, but rose in isolated pig brain mitochondria at 50 μmol/L, a discrepancy this dossier discloses rather than resolves.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: The pig-brain-mitochondria ATP increase is itself the key complicating result and is reported here rather than omitted; it is the only one of the three sources not showing ATP reduction.
  • At-risk subgroups: Not established.
  • Counter-evidence on record: The pig-brain-mitochondria finding directly complicates a simple "sertraline depletes ATP" narrative and is disclosed as an unresolved discrepancy rather than discarded.

Regulatory status

Not addressed in labeling.

Population evidence

Li & Couch, 2012 (rat hepatocytes): ATP rapidly and significantly depleted (p<0.001), attenuated by MPT blockade. Antioxidants (MDPI), 2023 (pig brain isolated mitochondria): Complex I-linked ATP content increased to 118.0±6.0% of control at 50 μmol/L sertraline, despite simultaneous partial Complex I inhibition at that same concentration range, an effect not mechanistically explained in that source. Sun et al., Communications Biology, 2025 (human cardiac organoids, 30 nM, 5 days): ATP-linked, basal, and maximal mitochondrial respiration significantly reduced.

Mechanism

Named for the depletion direction: MPT-driven uncoupling in hepatocytes; PGAM5-mediated mitochondrial fission impairing respiratory ATP synthesis in cardiac tissue. The pig-brain-mitochondria ATP increase is not mechanistically explained in that source and may reflect a compensatory shift toward substrate-level phosphorylation or an assay-specific feature of the isolated-mitochondria preparation; this is disclosed as unresolved rather than rationalized away.

Counter-evidence held on record

Never present this as a settled "sertraline drains cellular energy" claim. The most clinically relevant concentration data point (human cardiac organoids) shows reduction, but a same-tier isolated-mitochondria study in a different tissue found the opposite at a comparable concentration, and no human in vivo ATP or energy-expenditure measurement exists for sertraline. Shares underlying sources with Mitochondrial burden; see Overlap map.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Coenzyme Q10

    Where it comes from: Consumer nutrient-depletion articles listing CoQ10 as depleted by sertraline, with reasoning that "higher levels of CoQ10 have a significant antidepressant effect," a claim about CoQ10 helping depression, not evidence that sertraline lowers CoQ10.

    Why it fails: Sertraline has no mevalonate-pathway/HMG-CoA reductase mechanism of the kind that plausibly links statins to CoQ10 depletion, and no absorption-interference mechanism; no sertraline-specific or SSRI-class study measuring CoQ10 status was found during this review.

  • Magnesium

    Where it comes from: Consumer nutrient-depletion charts stating "fluoxetine, paroxetine, sertraline, citalopram, escitalopram, and venlafaxine all deplete magnesium," with reasoning based on magnesium's role as an NMDA-receptor antagonist (a description of magnesium's own pharmacology, not a mechanism for sertraline depleting it).

    Why it fails: No renal-wasting, absorption-interference, or hormonal mechanism for magnesium is documented for sertraline or any SSRI in the primary literature located. A sertraline-specific isolated-tissue pharmacology study located during this review (Wistar rat aortic/cardiac tissue) examined co-administered magnesium sulfate as a pharmacodynamic modulator of sertraline's cardiac effects, not as a depletion outcome, and does not support the claim.

  • Vitamin B2 (riboflavin)

    Where it comes from: A consumer drug-nutrient-depletion chart listing SSRIs, including Zoloft (sertraline), as inhibiting "absorption of vitamin B2."

    Why it fails: No gastric-pH, chelation, or transporter-competition mechanism for riboflavin absorption is documented for sertraline; no sertraline-specific or SSRI-class primary study was found during this review.

  • Vitamin B6 (pyridoxine)

    Where it comes from: A consumer article citing an unattributed statistic ("over 30% of patients on SSRIs have deficient B6 levels," effect size Cohen's d -0.47 to -0.59) with no traceable citation, alongside "all SSRIs deplete B6" framing.

    Why it fails: This specific statistic could not be traced to any primary or reviewed source during this review. The real B6-depression literature located concerns baseline B6 status and depression risk/symptoms, a condition-linked association, not an SSRI-induced depletion mechanism; no absorption-interference or renal-wasting mechanism is documented for sertraline.

  • Zinc

    Where it comes from: Consumer drug-nutrient-depletion charts listing zinc among nutrients depleted by SSRIs generally.

    Why it fails: The real zinc-depression literature located concerns zinc augmentation of imipramine (a tricyclic, not an SSRI) in treatment-resistant depression, i.e., baseline zinc deficiency as a factor affecting antidepressant response and zinc supplementation as adjunctive therapy, not sertraline lowering zinc. No absorption-interference, renal-wasting, or other depletion mechanism is documented for sertraline. One directly relevant source (a World Journal of Biological Psychiatry study of zinc and copper in drug-naive depression and antidepressant effects) returned a 403 error on every attempt during this review and could not be opened; it is listed in Sources as inaccessible and was not used to support any grade above white, per the prohibition on citing unread sources.

  • Vitamin B1 (thiamine), Vitamin B3 (niacin), Vitamin C, and Selenium

    Where it comes from: The same generic, uncited consumer drug-nutrient-depletion chart lists these four alongside B2, B6, B12, folate, zinc, and magnesium as depleted by "SSRIs" as a class, with no per-nutrient citation or mechanism given.

    Why it fails: No chelation, absorption-interference, hepatic-induction, renal-wasting, or cofactor-antagonism mechanism specific to sertraline, or documented at even a class level with drug-level stratification, was found for any of these four nutrients. A sertraline-specific selenium add-on randomized trial located during this review tests whether selenium supplementation improves sertraline's antidepressant/oxidative-stress effect, which does not establish that sertraline itself depletes selenium.

All references used above
  1. ZOLOFT (sertraline hydrochloride) tablets and oral solution, prescribing information. — FDA label, accessdata.fda.gov, Pfizer. Used for the pharmacokinetic basis, SIADH/hyponatremia labeling language, platelet-serotonin statement, and adverse-reaction percentages.
  2. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index, code N06AB06. — Confirms sertraline's ATC classification (N06AB, selective serotonin reuptake inhibitors) and defined daily dose (50 mg, oral).
  3. The risk of hyponatremia induced by SSRIs and SNRIs antidepressants: a systematic review and meta-analysis. — BMC Pharmacology and Toxicology, 2025. 38 observational studies, n=3,997,088. Sertraline-specific: 9 studies, event rate 2.52% (95% CI 0.81-7.55%); OR from 4 studies 2.346 (95% CI 2.178-2.527, p<0.001).
  4. The risk of hyponatremia induced by SSRIs and SNRIs antidepressants: a systematic review and meta-analysis (PMC full text, Table 2). — Same study as above; PMC copy used to extract sertraline-specific Table 2 event rates and odds ratios.
  5. Risk of antidepressant-induced hyponatremia in geriatric patients: a systematic review and meta-analysis. — BMC Geriatrics, 2026. 21 cohort studies, n=2,115,187 adults 60+. Sertraline-specific: any hyponatremia 9.32% (3 studies), clinically relevant 4.35% (2 studies); RR 4.03 (95% CI 2.55-6.39) and 4.73 (95% CI 2.48-9.02) vs non-users.
  6. Li Y, Couch L, et al. Mitochondrial dysfunction induced by sertraline, an antidepressant agent. — Toxicological Sciences, 2012;127(2):582. Rat primary hepatocytes and isolated rat liver mitochondria, sertraline 0-100 μM.
  7. Different Effects of SSRIs, Bupropion, and Trazodone on Mitochondrial Functions and Monoamine Oxidase Isoform Activity. — Antioxidants (MDPI), 2023;12(6):1208. Isolated pig brain mitochondria, sertraline 2.5-300 μmol/L alongside five other antidepressants; measured ETC complex activity, respiration, ATP, and MAO-A/B.
  8. Selective serotonin reuptake inhibitors induce cardiac toxicity through dysfunction of mitochondria and sarcomeres. — Communications Biology, 2025. Human pluripotent stem-cell-derived cardiomyocytes (2D and 3D organoids); fluoxetine, paroxetine, and sertraline (30 nM) tested at clinically relevant concentrations for 5 days.
  9. McGovern AS, Hamlin AS, Winter G. A review of the antimicrobial side of antidepressants and its putative implications on the gut microbiome. — Australian & New Zealand Journal of Psychiatry, 2019. Narrative review compiling primary in vitro MIC data specific to sertraline against multiple bacterial species.
  10. The effect of SSRI/SNRI antidepressant treatment on the gut microbiota of patients with major depressive disorder. — Communications Medicine, 2026. Two cohorts (MACS, MIND-Set), n=1,802 total, cross-sectional with meta-analysis. Sertraline included in the SSRI group but not analyzed individually (subgroups "too small and imbalanced").
  11. The effect of SSRI/SNRI antidepressant treatment on the gut microbiota of patients with major depressive disorder (PMC full text). — Same study as above; PMC copy used to confirm the explicit statement that compound-level (sertraline-specific) analysis was precluded.
  12. Rogers MAM, et al. Depression, antidepressant medications, and risk of Clostridium difficile infection. — BMC Medicine, 2013;11:121. Two-study design: 16,781 community-based older adults (Medicare-linked) and a 4,047-patient hospital case-control cohort. Individual-drug analysis found mirtazapine OR 2.14 and fluoxetine OR 1.92 significantly associated; sertraline not analyzed individually.
  13. Sherwood A, et al. Effects of sertraline on circulating markers of oxidative stress in depressed patients with chronic heart failure: a pilot study. — Journal of Cardiac Failure, 2011. Pilot, non-randomized, 52 depressed CHF patients (28 sertraline, 24 untreated) plus 40 nondepressed controls, 3-month follow-up.
  14. Impact of antidepressant treatment on complete blood count parameters and inflammatory ratios in adolescents with major depressive disorder. — ScienceDirect (abstract accessed). Prospective cohort, Walailak University Hospital, Thailand, n=45 drug-naive adolescents/young adults, fluoxetine or sertraline, 12 weeks.
  15. Wang X, et al. Ineffective erythropoiesis with reduced red blood cell survival in serotonin-deficient mice. — PNAS, 2011. Genetic (Tph1 knockout) serotonin-deficient mouse model, not an SSRI-treated model; used only as background mechanistic plausibility for serotonin's role in erythropoiesis, not as direct sertraline evidence.
  16. Study of the Serum Copper Levels in Patients with Major Depressive Disorder. — Case-control study, 114 MDD patients (69 depressive episode, 45 remission) and 50 healthy controls, 2006-2013. Found no significant serum copper difference by disease phase (0.81±0.27 vs 0.91±0.39 μg/mL, p>0.05); did not analyze treatment by individual drug.
  17. Evidence of promising biological-pharmacological activities of the sertraline-based copper complex: (SerH2)2[CuCl4]. — ScienceDirect. Synthetic coordination-chemistry study of a sertraline-copper complex as a candidate compound; not a study of patient copper status, checked and found not relevant to the Copper entry beyond confirming the absence of depletion-relevant data.
  18. Twayej AJ, Al-Hakeim HK, Al-Dujaili AH, Maes M. Lowered zinc and copper levels in drug-naive patients with major depression: Effects of antidepressants, ketoprofen and immune activation. — World Journal of Biological Psychiatry, 2020;21(2):127-138. PMID 31062629. Title-relevant to Zinc and Copper entries.Could not be opened on the original review or on a repair-pass re-attempt: Taylor & Francis Online returned a 403 error again; the PubMed abstract page rendered only page metadata with no abstract text; the Crossref works API returned bibliographic metadata (confirming the PMID and page range above) but no abstract field; Semantic Scholar and OpenAlex DOI lookups were blocked (429/blocked). Listed only, not used as supporting evidence beyond its title.
  19. Uzbekov MG, Misionzhnik EY, Maximova NM, Vertogradova OP. Biochemical profile in patients with anxious depression under the treatment with serotonergic antidepressants. — Human Psychopharmacology, 2006. PMID 16342231. Surfaced in a repair-pass PubMed search for "sertraline copper"; title-relevant to Copper but does not specify which serotonergic antidepressants were in the studied cohort.Could not be opened: the PubMed abstract page rendered only page metadata with no abstract text, NCBI eutils refused the request (disallowed by that host's robots.txt), and Europe PMC was blocked (429) on every attempt. Listed only, by title, not used as supporting evidence.
  20. Meng Y, et al. The Changes of Blood and CSF Ion Levels in Depressed Patients: a Systematic Review and Meta-analysis. — Molecular Neurobiology, 2024. Surfaced once in a repair-pass PubMed listing while searching for sertraline/SSRI iron literature; scope (which ions, and whether drug-treated versus untreated patients are stratified) could not be confirmed.Could not be pinned down or opened: subsequent PubMed, Crossref, and Europe PMC attempts to retrieve its PMID/DOI and abstract were all blocked before completion. Logged as an unverified lead for a future revision, not cited as evidence for Iron or Copper.
  21. Zinc deficiency and depression / antidepressant augmentation chapter. — Springer Nature book chapter reviewing zinc supplementation studies (Siwek et al. 2009, 2010) combined with imipramine, a tricyclic antidepressant, in treatment-resistant depression.
  22. Effect of sertraline on intradialytic hypotension: a randomized controlled trial. — DOAJ-indexed trial testing sertraline's effect on blood glucose, insulin, HDL-C, LDL-C, and triglycerides in depressed patients; checked while searching for a zinc-sertraline link and found not relevant to any trace-mineral entry.
  23. Comparison of the effects of sertraline and agomelatine on sleep quality, sexual functioning and metabolic parameters in patients with major depressive disorder. — Checked while searching for sertraline-specific melatonin data; title-relevant but not independently opened for melatonin-level data during this review.
  24. Antidepressant activity of teriparatide-unrelated mouse oxidative-stress study: sertraline and haloperidol brain/liver oxidative stress. — Journal of Basic and Clinical Physiology and Pharmacology. Animal study title relevant to the Oxidative stress entry.Could not be opened: the publisher's page returned a 405 error on every attempt during this review. Listed only, not used as supporting evidence.
  25. The effect of vitamin D supplementation with sertraline in patients of major depressive disorder: a 12-week prospective interventional study. — Indian Journal of Applied Research. Sertraline-specific vitamin D supplementation add-on study.Could not be fully opened: the PDF exceeded this session's fetchable URL/length limit on every attempt during this review. Listed only, not used as supporting evidence.
  26. Selective serotonin reuptake inhibitor use during pregnancy increases the risk of postpartum hemorrhage and anemia: a hospital-based cohort study. — Journal of Thrombosis and Haemostasis. Title relevant to Oxygen delivery/utilization.Could not be opened: returned a 429 rate-limit response and, on a second attempt via the abstract page, a 403 response. Listed only, not used as supporting evidence.
  27. Impact of nano-selenium supplementation add-on sertraline on depressive symptoms and oxidative stress in patients with major depressive disorder: a triple-blind randomized controlled trial. — PubMed listing. Sertraline-specific selenium add-on RCT, relevant to the Selenium fails-verification entry.Could not be opened: PubMed returned a bot-verification (reCAPTCHA) challenge page on every attempt during this review. Listed only, by title, not used as supporting evidence.
  28. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. — Original PubMed-indexed elderly SSRI hyponatremia incidence study, superseded for this dossier's grading by the two meta-analyses above, which independently pool and stratify sertraline.Could not be opened: PubMed returned a bot-verification (reCAPTCHA) challenge page on every attempt during this review. Not used as supporting evidence; superseded by sources 3-5 above.
  29. Impact of antidepressant treatment on complete blood count parameters and inflammatory ratios in adolescents with major depressive disorder (PubMed listing). — Same study as source 13 above; PubMed attempt made in addition to the successful ScienceDirect abstract fetch.PubMed itself returned a bot-verification (reCAPTCHA) challenge; the ScienceDirect abstract (source 13) was used instead and was successfully opened.
  30. Consumer drug-nutrient depletion sources used for the circulating-claim audit only (Tier D, never used to support a grade above white). — "7 Important Nutrients Depleted by Psychiatric Drugs" (Optimal Living Dynamics); a drug-nutrient depletion chart PDF (wschiro.com); "SSRIs systematically deplete the nutrients needed for mental health" (pathwaymap.com). All three opened and read in full to enumerate the specific claims rebutted in Fails verification.
  31. Crossref, Europe PMC, Semantic Scholar, and OpenAlex API queries (search and per-DOI lookup) for sertraline + copper and sertraline + iron/ferritin, across two research passes. — Bibliographic search only, attempted to confirm the absence of drug-specific literature for the Copper and Iron ungraded entries. Not citable studies; recorded here for audit transparency.All four APIs returned repeated 429/blocked responses on both the original review and a later, dedicated repair pass, including after a deliberate 60-second pause and retry. On the repair pass, the session's own network-proxy diagnostic endpoint confirmed these as gateway-level connection rejections (HTTP 403 on CONNECT) recurring within the same underlying session window as the original review, and PubMed's search-listing pages (intermittently readable) and the Crossref works API (intermittently reachable for a single DOI metadata lookup, with no abstract field) were the only channels that returned any usable content. Disclosed as a tooling limitation in the Copper and Iron entries.